Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xianlingcao
- Development stage
- Phase 2
- Lead developer
- Tianjin Tianjiao Pharmaceutical
- Administration
- Oral
01
Overview
Xianlingcao is a Traditional Chinese Medicine (TCM) granule formulation developed by Tianjin Tianjiao Pharmaceutical for the treatment of primary non-small cell lung cancer (NSCLC). It is specifically designed for patients diagnosed with the "Qi stagnation and blood stasis" syndrome according to TCM principles. The drug is typically administered orally as an adjuvant therapy in combination with standard chemotherapy. Clinical investigations, such as trial CTR20170065, focus on exploring its effective indications and safety profile in this patient population.
- Brand names
- Xianlingcao
- Other names
- Xianlingcao Granules仙苓草颗粒
Beyond the preview
Go deeper on xianlingcao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xianlingcao.